GE HealthCare rebounded with 300B won sales last year

Sales stalled due to the medical-gov't conflict in 2024…successfully rebounded in one year

In addition to selling equipment, the company recovered momentum with expanded service·platform

Unveiled its new technology·expanded hospital collaborations, expanding its mid-to-long-term pillars of business growth

GE HealthCare, which is pushing for an "Integrated Precision Healthcare" that combines hardware with digital solutions, successfully led a sales rebound last year.

Following the medical-government conflict that hit the industry in 2024, the expansion of communication with hospitals and clinics in South Korea via digital platforms is cited as a key factor in improving performance.

​After the 2024 medical-government crisis…V-shaped rebound in one year 

According to recently released audit reports, GE HealthCare Korea's sales in 2025 reached KRW 317.1 billion, a 14.9% increase from KRW 275.8 billion the previous year.

After sales dropped 6.8% in 2024 to KRW 295.9 billion from 2023, the company quickly surpassed the KRW 300 billion the following year, signaling a significant recovery.

Operating profit also increased by 13.4%, from KRW 16.86 billion in 2024 to KRW 19.13 billion in 2025. During the same period, net income rose from KRW 14.57 billion to KRW 17.09 billion. 

However, the operating profit margin remained stable at around 6.0% (6.1% in 2023, 6.1% in 2024, and 6.0% in 2025), indicating steady maintenance rather than a drastic improvement in profitability.

GE HealthCare Korea's 4-Year Sales & Operating Profits: GE HealthCare Korea's sales in 2025 reached KRW 317.1 billion. Source: FSS DART, unit: KRW 100 million (Audit report re-graphed by Daily Pharm)

As the medical-government conflict issues gradually resolve, the company's efforts to strengthen capabilities and improve its internal structure have been proven through these figures, suggesting a structural rebound rather than a simple recovery.

In 2024, the decline in sales was largely due to a decrease in product sale, which dropped from KRW 193.8 billion to KRW 170.8 billion.

In contrast, service sales increased from KRW 102.1 billion to KRW 104.9 billion during the same period, acting as a buffer while equipment sales were shaken.

In 2025, both products and services rebounded simultaneously. Product sales reached KRW 203.9 billion, and service sales rose to KRW 113.2 billion.

GE HealthCare Korea's Product Sales & Service Sales Ratio: GREEN-product sales, BLUE-service sales. Source: FSS DART, Unit: KRW 100 million. (Audit report re-graphed by Daily Pharm)

GE HealthCare strengthens platform strategy…Expanding hospital collaborations

GE HealthCare is shifting its weight from a structure centered on equipment sales to a platform-based strategy.

The core of this is the 'D3 Strategy,' which encompasses Device, Disease, and Digital. It aims to use AI to improve quality, support customized treatment, and ultimately integrate data into a cloud-based platform.

Globally, GE HealthCare has obtained FDA clearance for 100 AI-enabled medical devices, setting a record for the most listings in four consecutive years.

A representative technology, 'AIR Recon DL,' which offers both reduced MRI scan times and improved image quality, has been introduced to more than 20 medical institutions in Korea.

SPI index displayed on the CARESCAPE Canvas

Additionally, in February, the Surgical Pleth Index (SPI), a monitoring indicator that quantifies pain responses during surgery, was listed as a "New Medical Technology." This expanded the company's presence beyond imaging into the operating room and patient monitoring sectors.

The technology portfolio is shifting from simple imaging equipment to clinical decision-support tools.

Consequently, partnerships with major hospitals are expanding beyond simple supply contracts into a system of "Reference Sites" and cooperative hospital networks.

For example, ​Dongtan City Hospital was designated as an Asian regional reference site in January. Its AI Radiology Center serves as a hub where customers from Korea, ASEAN, Australia, and New Zealand can refer to operational cases.

Gumi Gangdong Hospital signed an MOU for clinical cooperation and equipment operational efficiency. ​Daegu Miracle Women's Clinic is partnering to advance infertility treatment based on high-end ultrasound technology.

These structures integrates everything from equipment supply to operational training, protocol sharing, and the expansion of clinical utilization into a single package.

Yong-duck Kim, President & CEO of GE HealthCare Korea, stated, "The designation of Dongtan City Hospital as an Asian regional reference site signifies that the equipment operation and clinical environment of medical institutions in South Korea have been recognized as excellent global reference cases," and added, "GE HealthCare will continue to actively support Dongtan City Hospital in maintaining efficient and stable equipment operation and building a sustainable medical environment."